methylazoxymethanol and Brain-Diseases

methylazoxymethanol has been researched along with Brain-Diseases* in 8 studies

Reviews

2 review(s) available for methylazoxymethanol and Brain-Diseases

ArticleYear
Amyloid precursor protein processing in vivo--insights from a chemically-induced constitutive overactivation of protein kinase C in Guinea pig brain.
    Current medicinal chemistry, 2003, Volume: 10, Issue:10

    Aberrant proteolytical processing of the amyloid precursor protein (APP) gives rise to beta-amyloid peptides, which form deposits characteristic for the brains of Alzheimer's disease patients. From in vitro studies, protein kinase C (PKC) is known for almost 20 years to be involved the secretory pathway of APP processing, resulting in the reduced generation of beta-amyloid peptides. However, the toxicity of activators of PKC, such as phorbol esters, has prevented to test the hypothesis of an inverse regulation of secretory APP processing and beta-amyloid generation in vivo. Here we present an animal model which allows to reveal the function of PKC in the proteolytical processing of APP in vivo. Studies by Johnstone and Coyle from the early 1980s have shown that treatment of pregnant rats with methylazoxymethanol acetate (MAM) results in the induction of neocortical microencephalopathy of the offsprings. Later on, the constitutive overactivation of PKC isoforms was described in affected brain structures of these animals. This led to the idea to study the APP processing under conditions of overactivated PKC in the brains of such animals in vivo. However, in mice and rats one can follow the generation of secretory APP products but the detection of rodent beta-amyloid peptides is delicate. Therefore, we adapted the MAM model to guinea pigs, which have a human beta-amyloid sequence, and investigated the relation between secretory APP processing and beta-amyloid generation in vivo. In the brains of microencephalic guinea pigs we observed increased levels of secretory APP fragments but no change in the concentration of beta-amyloid peptides. Our results indicate that both pathways of APP processing are differentially controlled under these experimental conditions in vivo.

    Topics: Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Brain; Brain Diseases; Disease Models, Animal; Endopeptidases; Enzyme Activation; Female; Guinea Pigs; Isoenzymes; Methylazoxymethanol Acetate; Microcephaly; Mutation; Peptide Hydrolases; Pregnancy; Protein Kinase C; Protein Processing, Post-Translational

2003
Developmental models of brain dysfunctions induced by targeted cellular ablations with methylazoxymethanol.
    Physiological reviews, 1997, Volume: 77, Issue:1

    Abnormal brain development represents one of the major causes of neurological disorders in humans, and determining the factors responsible for generating specific brain malformations represents a formidable task for developmental neurobiology. The knowledge of the precise neurogenetic time table and the use of toxins, like methylazoxymethanol, able to interfere with neuroepithelial cells entering their last mitotic cycle, have allowed for targeted neuronal ablations in specific brain areas of the central nervous system (CNS) when administered at different gestational or postnatal days in various animal species. Of particular relevance are the studies in which ablations of neuronal populations of cortex, hippocampus, and cerebellum have been made. The results obtained show that these early ablations induce a number of neuroanatomic, neurochemical, and electrophysiological changes that give us the possibility to unravel the biochemical strategies utilized by surviving neurons to adapt to the perturbated environment. Most striking are the findings that target deprivation does not affect the survival of afferent neurons in the CNS (except for neurons of the lateral geniculate nucleus), in sharp contrast to the notion of target dependence for peripheral nervous system neurons. Animals showing selective ablations in the Ammon's horn of the hippocampus allow us to understand the complex biochemical pathways leading to changes in activity-dependent synaptic plasticity, and the data underscore the fundamental role of diverse Ca(2+)-dependent protein kinases, and their substrates, in modulating pre- and postsynaptic events during induction and maintenance of long-term potentiation (LTP). Because LTP represents a useful model to study molecular substrates of learning and memory, this animal model might be of relevance in understanding cognitive brain dysfunctions.

    Topics: Animals; Brain Diseases; Carcinogens; Methylazoxymethanol Acetate; Models, Neurological

1997

Other Studies

6 other study(ies) available for methylazoxymethanol and Brain-Diseases

ArticleYear
Neurogenesis in cerebral heterotopia induced in rats by prenatal methylazoxymethanol treatment.
    Cerebral cortex (New York, N.Y. : 1991), 2003, Volume: 13, Issue:7

    We have previously demonstrated that the antiproliferative agent methylazoxymethanol acetate (MAM) is able to induce in rats cerebral heterotopia that share striking similarities with those observed in human periventricular nodular heterotopia (PNH), a cerebral dysgenesis frequently observed in human patients affected by drug-resistant focal epilepsy. In this study, we investigated the time-course of neurogenesis in the cerebral heterotopia of MAM-treated rats, with the idea of understanding why PNH develop in human patients. For these goals, we analyzed the cytoarchitectural features, the time of neurogenesis and the cellular phenotype of the heterotopia, by means of BrdU immunocytochemistry and confocal immunofluorescence experiments. Our data demonstrate that the different types of heterotopia in MAM-treated rats are formed through the same altered neurogenetic process, which follows quite organized neurogenetic gradients. The MAM-induced ablation of an early wave of cortical neurons is sufficient to alter per se the migration and differentiation of subsequently generated neurons, which in turn set the base for the formation of the different heterotopic structures. The neurogenesis of MAM-induced heterotopia may explain the origin and intrinsic epileptogenicity of periventricular nodular heterotopia in human patients.

    Topics: Animals; Brain Diseases; Bromodeoxyuridine; Cerebral Cortex; Choristoma; Disease Models, Animal; Female; Methylazoxymethanol Acetate; Microscopy, Confocal; Morphogenesis; Neurons; Phenotype; Pregnancy; Rats; Rats, Sprague-Dawley

2003
Characterization of heterotopic cell clusters in the hippocampus of rats exposed to methylazoxymethanol in utero.
    Epilepsy research, 2000, Volume: 39, Issue:2

    Cortical disorganization represents one of the major clinical findings in many children with medically intractable epilepsy. To study the relationship between seizure propensity and abnormal cortical structure, we have begun to characterize an animal model exhibiting aberrant neuronal clusters (heterotopia) and disruption of cortical lamination. In this model, exposing rats in utero to the DNA methylating agent methylazoxymethanol acetate (MAM; embryonic day 15) disrupts the sequence of normal brain development. In MAM-exposed rats, cells in hippocampal heterotopia exhibit neuronal morphology and do not stain with immunohistochemical markers for glia. In hippocampal slices from MAM-exposed animals, extracellular field recordings within heterotopia suggest that these dysplastic cell clusters make synaptic connections locally (i.e. within the CA1 hippocampal subregion) and also make aberrant synaptic contact with neocortical cells. Slice perfusion with bicuculline or 4-aminopyridine leads to epileptiform activity in dysplastic cell clusters that can occur independent of input from CA3. Taken together, our findings suggest that neurons within regions of abnormal hippocampal organization are capable of independent epileptiform activity generation, and can project abnormal discharge to a broad area of neocortex, as well as hippocampus.

    Topics: 4-Aminopyridine; Animals; Bicuculline; Brain Diseases; Choristoma; Convulsants; Electrophysiology; Epilepsy; Female; Hippocampus; Methylazoxymethanol Acetate; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Synapses

2000
Glutamate receptors in dysplasic cortex: an in situ hybridization and immunohistochemistry study in rats with prenatal treatment with methylazoxymethanol.
    Brain research, 1998, Jan-26, Volume: 782, Issue:1-2

    Injection of the antimitotic drug methylazoxymethanol (MAM) in the pregnant rat at E14 leads in the offsprings to a severe malformation with microcephaly and cortical heterotopiae in the white matter and in the CA1 field of the hippocampus. These animals suffer cognitive and epileptic disorders. Since these pathologies have been associated with glutamatergic transmission abnormalities, we have examined by in situ hybridization and immunohistochemistry the distribution and expression levels of several glutamate receptors subunits in these rats. Examination of the GluR2 flip and flop, NR1, NR2A and NR2B subunit gene transcripts showed a qualitatively similar distribution in both the neocortex and hippocampus of MAM and control rats. Quantitative analysis revealed an altered proportion of the GluR2 flip and flop subunits in the CA1 region of MAM animals as compared to controls. Moreover, a 26% reduction in the expression of the NR1 subunit and a 40% increase in the expression of the GluR2 flip subunit were noted in cortical heterotopiae, as compared to the adjacent neocortex. Immunostaining for GluR2/3, NR1 or NR2 showed, in both MAM and control animals, that glutamate receptors were mainly concentrated in the soma and dendrites of neocortical and hippocampal pyramidal cells, including in heterotopiae, and in the apical dendrites of hippocampal granule cells. Abnormalities in the expression of glutamate receptor subtypes in cortical heterotopiae and in the hippocampal CA1 region could contribute to functional disorders previously reported in MAM animals such as memory impairments and epilepsy.

    Topics: Animals; Brain Diseases; Cerebral Cortex; Choristoma; Female; Hippocampus; Immunohistochemistry; In Situ Hybridization; Methylazoxymethanol Acetate; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Receptors, Glutamate; RNA, Messenger

1998
Altered connections between neocortical and heterotopic areas in methylazoxymethanol-treated rat.
    Epilepsy research, 1998, Volume: 32, Issue:1-2

    We are currently investigating various treatments which could determine, in the rat brain, structural abnormalities mimicking those reported in human brain dysgeneses. We can induce the formation of neuronal heterotopia in the progeny of rats by means of a double injection of the cytotoxic agent methylazoxymethanol acetate (MAM) on embryonic day 15. We have now investigated the anatomical connections of these heterotopia by means of anterograde and retrograde tract tracing techniques. The induced heterotopia along the border of the lateral ventricles shared common anatomical features with the periventricular nodules in human periventricular or subcortical nodular heterotopia (PNH). The tract tracing data demonstrated the existence of reciprocal connections between the neuronal heterotopia and the ipsilateral and contralateral cortical areas, and the presence of abnormal cortico-hippocampal and cortico-cortical connections. On the basis of the connectivity patterns, it may be speculated that some cells in the heterotopia could be neurons originally committed to the cortex, that were interrupted in their migration by the MAM treatment. Given the common morphological features seen in human PNH and MAM-induced brain heterotopia, the anatomical and developmental analysis of MAM-treated rats may shed light on the mechanisms by which human brain dysgeneses develop in human patients.

    Topics: Animals; Axonal Transport; Brain; Brain Diseases; Choristoma; Disease Models, Animal; Female; Functional Laterality; Gestational Age; Humans; Methylazoxymethanol Acetate; Neocortex; Neurons; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Teratogens

1998
Potentiating effects of methamphetamine on the hyperactivity of microencephalic rats treated prenatally with methylazoxymethanol: possible implication of hyperdopaminergia.
    Brain research, 1995, Jan-23, Volume: 670, Issue:1

    Microencephalic rats induced by methylazoxymethanol (MAM) were observed to have notable hyperactivity compared to control rats, as measured by several behavioral parameters in an automated field apparatus. Acute injection of the stimulant drug, methamphetamine (MAP), produced an increase in the incidence of locomotion and rearing in control rats, and this stimulatory effect of MAP on motor activity was markedly potentiated in MAM rats. Chronic MAP treatment did not change D1 or D2 dopamine receptor densities in either control or MAM rats. From these results, it was suggested that augmented dopaminergic functions may contribute to the hyperactivity seen in MAM rats.

    Topics: Alkylating Agents; Animals; Behavior, Animal; Brain Diseases; Methamphetamine; Methylazoxymethanol Acetate; Motor Activity; Neurons; Rats; Rats, Wistar; Receptors, Dopamine

1995
Methylazoxymethanol (MAM)-induced brain lesion and oral dyskinesia in rats.
    Psychopharmacology, 1990, Volume: 100, Issue:1

    The effects of methylazoxymethanol (MAM)-induced brain lesions on vacuous chewing movements (VCM) were examined in rats given chronic haloperidol treatment (0.1 or 1 mg/kg/day) for 18 months. At the end of the experiment striatal, pallidal, and nigral activities of glutamate decarboxylase (GAD) were measured. MAM-lesioned rats had an elevated rate of VCMs compared to unlesioned controls. This effect was stable during the whole 18-month experiment. In unlesioned control rats chronic haloperidol produced a gradual increase in VCM rates, but this effect was not further exacerbated in MAM-lesioned animals. After chronic haloperidol treatment with the higher dose (1 mg/kg/day) GAD activity was reduced in substantia nigra (-20%), globus pallidus (-35%), and striatum (-26%) of unlesioned rats. MAM caused a reduction of GAD activity in substantia nigra (-29%) and globus pallidus (-29%). Chronic haloperidol did not influence these effects of MAM-induced lesion. The present results show that a MAM-induced brain lesion, in contrast to cortical ablations, cannot be used to amplify the haloperidol-induced VCM increase or influence the nigral GAD activity in a rat model for tardive dyskinesia.

    Topics: Animals; Azo Compounds; Behavior, Animal; Brain Diseases; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Glutamate Decarboxylase; Haloperidol; Methylazoxymethanol Acetate; Pregnancy; Rats; Substantia Nigra

1990